Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: Results from the COIN study

Gut

Volumn 63, Issue 1, 2014, Pages 72-79

  Van Der Valk, Mirthe Emilie ^a   Mangen, Marie Josée J ^a   Leenders, Max ^a   Dijkstra, Gerard ^b   Van Bodegraven, Ad A ^c   Fidder, Herma H ^a   De Jong, Dirk J ^d   Pierik, Marieke ^e   Van Der Woude, C Janneke ^f   Romberg Camps, Mariëlle J L ^g   Clemens, Cees H M ^h   Jansen, Jeroen M ^h   Mahmmod, Nofel ⁱ   Van De Meeberg, Paul C ^j   Van Der Meulen De Jong, Andrea E ^k   Ponsioen, Cyriel Y ^l   Bolwerk, Clemens J M ^m   Vermeijden, J Reinoud ⁿ   Siersema, Peter D ^a   Van Oijen, Martijn G H ^a,o   Oldenburg, Bas ^a   more..

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g Sittard Geleen Heerlen   (Netherlands)

^h Diaconessenhuis ^*  (Netherlands)

ⁱ ST ANTONIUS HOSPITAL   (Netherlands)

^j SLINGELAND HOSPITAL   (Netherlands)

^k LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^l ACADEMIC MEDICAL CENTER   (Netherlands)

^m REINIER DE GRAAF HOSPITAL   (Netherlands)

ⁿ MEANDER MEDICAL CENTER   (Netherlands)

^o UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; CLINICAL ASSESSMENT; COST BENEFIT ANALYSIS; COST OF ILLNESS; CROHN DISEASE; DRUG COST; FEMALE; FOLLOW UP; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE SURGERY; MAJOR CLINICAL STUDY; MALE; MEDICAL LEAVE; MIDDLE AGED; PRIORITY JOURNAL; SELF REPORT; TREATMENT OUTCOME; ULCERATIVE COLITIS;

CROHN'S DISEASE; ECONOMIC EVALUATION; INFLAMMATORY BOWEL DISEASE; ULCERATIVE COLITIS;

ABSENTEEISM; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; COLITIS, ULCERATIVE; COST OF ILLNESS; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HEALTH EXPENDITURES; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NETHERLANDS; QUESTIONNAIRES; SICK LEAVE; YOUNG ADULT;

EID: 84889636549     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-303376     Document Type: Article

References (33)

1. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002;8:244-50. (Pubitemid 34784976)
2. Bassi A, Dodd S, Williamson P, et al. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004;53:1471-8. (Pubitemid 39265268)
3. Juan J, Estiarte R, Colome E, et al. Burden of illness of Crohn's disease in Spain. Dig Liver Dis 2003;35:853-61. (Pubitemid 41070490)
4. Odes S, Vardi H, Friger M, et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterol 2006;131:719-28. (Pubitemid 44307060)
5. Blomqvist P, Ekbom A. Inflammatory bowel diseases: health care and costs in Sweden in 1994. Scand J Gastroenterol 1997;32:1134-9. (Pubitemid 27523846)
6. Gibson TB, Ng E, Ozminkowski RJ, et al. The direct and indirect cost burden of Crohn's disease and ulcerative colitis. J Occup Environ Med 2008;50:1261-72.
7. Stark R, Konig HH, Leidl R. Costs of inflammatory bowel disease in Germany. Pharmacoeconomics 2006;24:797-814. (Pubitemid 44232107)
8. Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterol 2008;135:1493-9.
9. Lichtenstein GR, Yan S, Bala M, et al. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004;99:91-6. (Pubitemid 38679108)
10. Peyrin-Biroulet L, Oussalah A, Williet N, et al. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut 2011;60:930-6.
11. Targownik LE, Singh H, Nugent Z, et al. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol 2012;10:1228-35.
12. Feagan BG, Bala M, Yan S, et al. Unemployment and disability in patients with moderately to severely active Crohn's disease. J Clin Gastroenterol 2005;39:390-5. (Pubitemid 40548076)
13. Feagan BG, Reilly MC, Gerlier L, et al. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study. Aliment Pharmacol Ther 2010;31:1276-85.
14. Lichtiger S, Binion DG, Wolf DC, et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. Aliment Pharmacol Ther 2010;32:1228-39.
15. Enthoven AC, van d V. Going Dutch - managed-competition health insurance in the Netherlands. N Engl J Med 2007;357:2421-3. (Pubitemid 350272779)
16. Tsiachristas A, Hipple-Walters B, Lemmens KM, et al. Towards integrated care for chronic conditions: Dutch policy developments to overcome the (financial) barriers. Health Policy 2011;101:122-32.
17. van Schaik FD, van Oijen MG, Smeets HM, et al. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut 2012;61:235-40.
18. Baars JE, Looman CW, Steyerberg EW, et al. The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study. Am J Gastroenterol 2011;106:319-28.
19. Statistics Netherland.2011. http://www.cbs.nl (accessed Sept 2012).
20. Hakkaart-van Roijen L, Tan SS, Bouwmans CAM. Handleiding voor kostenonderzoek, methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. College voor zorgverzekeringen Geactualiseerde versie. 2010.
21. Drummond M, Manca A, Sculpher M. Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies. Int J Technol Assess Health Care 2005;21:165-71. (Pubitemid 40656544)
22. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterol 2008;135:1907-13.
23. Bernstein CN, Loftus EV Jr, Ng SC, et al. Hospitalisations and surgery in Crohn's disease. Gut 2012;61:622-9.
24. Weiss RJ, Stark A, Wick MC, et al. Orthopaedic surgery of the lower limbs in 49,802 rheumatoid arthritis patients: results from the Swedish National Inpatient Registry during 1987 to 2001. Ann Rheum Dis 2006;65:335-41. (Pubitemid 43268222)
25. Da SE, Doran MF, Crowson CS, et al. Declining use of orthopedic surgery in patients with rheumatoid arthritis? Results of a long-term, population-based assessment. Arthritis Rheum 2003;49:216-20. (Pubitemid 36418280)
26. Boonen A, Matricali GA, Verduyckt J, et al. Orthopaedic surgery in patients with rheumatoid arthritis: a shift towards more frequent and earlier non-joint-sacrificing surgery. Ann Rheum Dis 2006;65:694-5.
27. Boonen A, Dagnelie PC, Feleus A, et al. The impact of inflammatory bowel disease on labor force participation: results of a population sampled case-control study. Inflamm Bowel Dis 2002;8:382-9. (Pubitemid 36411024)
28. Internet world statistics. 2011. http://www.internetworldstats.com (accessed Sept 2012).
29. Molinie F, Gower-Rousseau C, Yzet T, et al. Opposite evolution in incidence of Crohn's disease and ulcerative colitis in Northern France (1988-1999). Gut 2004;53:843-8. (Pubitemid 38662134)
30. Bernstein CN, Wajda A, Svenson LW, et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol 2006;101:1559-68. (Pubitemid 43980630)
31. Gearry RB, Richardson A, Frampton CM, et al. High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study. Inflamm Bowel Dis 2006;12:936-43. (Pubitemid 44498282)
32. Cosnes J. Crohn's disease phenotype, prognosis, and long-term complications: what to expect? Acta Gastroenterol Belg 2008;71:303-7.
33. Schwartz DA, Pemberton JH, Sandborn WJ. Diagnosis and treatment of perianal fistulas in Crohn disease. Ann Intern Med 2001;135:906-18. (Pubitemid 33070686)